This browser doesn't support Spotify Web Player. Switch browsers or download Spotify for your desktop.

eViralHepatitis Review

By eViralHepatitis Review

Experts in viral hepatitis review topics in hepatitis C, hepatitis B, and coinfection using patient case scenarios. Certified for CME/CE credit.

  1. 1.
    HBV Spring 2020: State of the Research05/26/2020
    15:15
  2. 2.
    HCV: Management Beyond the Liver04/10/2020
    22:35
  3. 3.
    HCV: Management Beyond the Liver03/04/2020
    21:58
  4. 4.
    Avoiding “MELD Purgatory”04/19/2019
    22:45
  5. 5.
    Clinical Perspectives on Barriers To HBV Care04/10/2019
    23:59
  6. 6.
    Clinical Insight: Engaging PWID in HCV Care12/28/2018
    25:40
  7. 7.
    In the Clinic: Identifying & Managing HCV Complications10/26/2018
    28:09
  8. 8.
    New Options for Patients with “Hard-To-Treat” Hepatitis C Infection01/25/2018
    32:58
  1. 9.
    Using Real World Data to Individualize HCV Management11/30/2017
    33:59
  2. 10.
    Using Real World Data to Individualize HCV Management09/28/2017
    30:00
  3. 11.
    Clinical Insights: HCV and Substance Use Disorder08/11/2017
    24:27
  4. 12.
    Clinical Approaches to HBV Therapy05/25/2017
    32:21
  5. 13.
    HBV: Addressing Current Gaps in Diagnosis and Linkage to Care03/30/2017
    31:50
  6. 14.
    Extrahepatic Manifestations of Hepatitis C: Screening and Management10/27/2016
    31:53
  7. 15.
    Emerging Therapeutic Approaches for Chronic Hepatitis B08/25/2016
    33:23
  8. 16.
    New Approaches to the Diagnosis and Management of Chronic HBV Infection07/14/2016
    30:23
  9. 17.
    Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study05/26/2016
    16:09
  10. 18.
    Resistance Analysis for Ledipasvir/Sofosbuvir containing regimens in patients infected with chronic HCV who have advanced liver disease or are post Liver Transplant (SOLAR-1 and 2 STUDIES)05/26/2016
    9:43
  11. 19.
    High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals05/26/2016
    13:15
  12. 20.
    Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations04/14/2016
    34:43
  13. 21.
    Screening for HCV and HBV Infection in the Clinic02/18/2016
    32:33
  14. 22.
    Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 201512/29/2015
    12:47
  15. 23.
    Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 201512/29/2015
    7:19
  16. 24.
    Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 201512/29/2015
    8:20
  17. 25.
    The New DAAs and HCV Genotype 2/3 Patients11/24/2015
    33:59
  18. 26.
    INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION02/19/2015
    19:15
  19. 27.
    INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION02/19/2015
    18:40
  20. 28.
    INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION02/19/2015
    14:54
  21. 29.
    INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY01/21/2015
    17:42
  22. 30.
    INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY01/21/2015
    18:11
  23. 31.
    Highlights from the 2014 EASL Meeting07/30/2014
    36:40
  24. 32.
    HCV Screening and Natural History05/27/2014
    33:36
  25. 33.
    Susanna Naggie, MD Discussed HBV and HCV Coverage at AASLD03/31/2014
    41:49
  26. 34.
    Cure of Hepatitis B: Is it Achievable?01/28/2014
    36:06
  27. 35.
    The Role of Prediction Models: Best practices in Identifying Cirrhosis and HCC in Patients Infected with HBV11/26/2013
    29:46
  28. 36.
    European Association for the Study of the Liver HCV Update09/26/2013
    37:06
  29. 37.
    Hepatitis C and Host Genetics12/20/2012
    35:23
  30. 38.
    Reactivation of Hepatitis B Virus Infection10/04/2012
    37:04
  31. 39.
    HCV/HIV Coinfection07/31/2012
    36:30
  32. 40.
    Occult Hepatitis B Virus Infection05/30/2012
    33:56
  33. 41.
    Dr. Tram T. Tran will cover issues related to Hepatitis B and Pregnancy03/27/2012
    35:26

Listen to eViralHepatitis Review now.

Listen to eViralHepatitis Review in full in the Spotify app